Bristol-Myers Squibb Co. (NYSE:BMY)

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

Over the past three decades, the unlimited investing potential of biotechnology was all about growth. Companies could grow from nothing to see untold billions of dollars selling cures and treatments ...
Read Full Story »

Major Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Defensive Stocks Standing Strong as Broader Stock Market Indexes Tank

When the stock market is taking it on the chin, it's often useful to take note of which stocks are rallying despite the negativity. This is a time when many ...
Read Full Story »

Short Sellers Up the Ante in Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Big Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Many Top Pharma & Biotechs Rise as Drug Price Disclosure Thrown Out

While the public wants more pharmaceuticals and biotech advancements to treat the endless number of ailments or to extend their lives, there is a simultaneous push to make drugs more ...
Read Full Story »

Short Sellers Seek Direction on Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Big Pharma Sees a Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Big Pharma Short Sellers Hike Their Bets

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Alibaba, Baidu, Bristol-Myers, Cimarex, Deere, Deutsche Bank, Micron, NeoPhotonics, Target, United Continental and More

Stocks were down another 0.6% or so in Dow Jones industrial average and S&P 500 futures on Monday morning as further realizations and expectations normalize into a belief that the ...
Read Full Story »

Big Pharma Scares Off Short Sellers

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Amex, Bristol-Myers, Celgene, Cognizant, EA, Fortinet, Lyft, Target, Tilray, Walmart and More

Stocks were indicated to open higher after a strong payrolls report on Friday morning. Despite a pullback this week, the markets remain near all-time highs and investors have solid double-digit ...
Read Full Story »

Big Pharma Scares Off Short Sellers

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

When the stock market is hitting record highs, it's important to remember that it's really a market of stocks rather than a stock market. Not all companies are created equal. ...
Read Full Story »

Unbelievable Swings in Big Pharma Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »